Page last updated: 2024-10-28

hydroxyurea and Bleeding

hydroxyurea has been researched along with Bleeding in 53 studies

Research Excerpts

ExcerptRelevanceReference
"Therapeutic options for patients with polycythemia vera (PV) and essential thrombocythemia (ET) resistant or intolerant to hydroxyurea are limited."9.19Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. ( Alvarez-Larrán, A; Ancochea, A; Angona, A; Antelo, ML; Bellosillo, B; Besses, C; Burgaleta, C; Cervantes, F; Durán, MA; Ferrer-Marín, F; Gómez, M; Gómez-Casares, MT; Hernández-Boluda, JC; Marcote, B; Martínez-Avilés, L; Martínez-Trillos, A; Mata, MI; Senín, A; Vicente, V; Xicoy, B, 2014)
"Hydroxyurea is effective in preventing thrombosis in high-risk patients with essential thrombocythemia."9.08Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. ( Barbui, T; Cortelazzo, S; Finazzi, G; Galli, M; Rodeghiero, F; Ruggeri, M; Vestri, O, 1995)
"Hydroxyurea is the standard treatment in high-risk patients with polycythemia vera."9.01Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. ( Barbui, T; Carobbio, A; De Stefano, V; Ferrari, A; Finazzi, G; Ghirardi, A; Masciulli, A; Vannucchi, AM, 2019)
"Hydroxyurea is an old drug that is often used to control essential thrombocythemia and polycythemia vera in patients with high-risk disease."8.83Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia. ( Dingli, D; Tefferi, A, 2006)
"Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease-progression is unknown."8.12Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. ( Alvarez-Larrán, A; Angona, A; Arellano-Rodrigo, E; Ayala, R; Bellosillo, B; Caballero, G; Carreño-Tarragona, G; Cuevas, B; Del Orbe-Barreto, R; Ferrer-Marín, F; Fox, ML; García, R; García-Gutiérrez, V; García-Hernández, C; Garrote, M; Gasior, M; Gómez, M; Gómez-Casares, MT; Guerrero, L; Hernández-Boluda, JC; Magro, E; Martínez, CM; Mata-Vazquez, MI; Murillo, I; Pereira, A; Pérez-Encinas, M; Pérez-López, R; Ramírez, MJ; Raya, JM; Xicoy, B, 2022)
"Therapeutic options for patients with polycythemia vera (PV) and essential thrombocythemia (ET) resistant or intolerant to hydroxyurea are limited."5.19Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. ( Alvarez-Larrán, A; Ancochea, A; Angona, A; Antelo, ML; Bellosillo, B; Besses, C; Burgaleta, C; Cervantes, F; Durán, MA; Ferrer-Marín, F; Gómez, M; Gómez-Casares, MT; Hernández-Boluda, JC; Marcote, B; Martínez-Avilés, L; Martínez-Trillos, A; Mata, MI; Senín, A; Vicente, V; Xicoy, B, 2014)
" As compared with hydroxyurea plus aspirin, anagrelide plus aspirin was associated with increased rates of arterial thrombosis (P=0."5.11Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. ( Bareford, D; Buck, G; Campbell, PJ; East, CL; Green, AR; Grigg, AP; Harrison, CN; Reilly, JT; Revell, P; van der Walt, JD; Wheatley, K; Wilkins, BS; Woodcock, BE, 2005)
"Hydroxyurea is effective in preventing thrombosis in high-risk patients with essential thrombocythemia."5.08Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. ( Barbui, T; Cortelazzo, S; Finazzi, G; Galli, M; Rodeghiero, F; Ruggeri, M; Vestri, O, 1995)
"Hydroxyurea is the standard treatment in high-risk patients with polycythemia vera."5.01Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. ( Barbui, T; Carobbio, A; De Stefano, V; Ferrari, A; Finazzi, G; Ghirardi, A; Masciulli, A; Vannucchi, AM, 2019)
" The aim of this study was to meta-analyze currently available data comparing anagrelide to hydroxyurea for reduction of rates of thrombosis, bleeding and death among patients with ET."4.91Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis. ( Chai-Adisaksopha, C; Garcia, D; Samuelson, B, 2015)
"Hydroxyurea is an old drug that is often used to control essential thrombocythemia and polycythemia vera in patients with high-risk disease."4.83Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia. ( Dingli, D; Tefferi, A, 2006)
" Results of the first phase III trial (PT1) that compared anagrelide/aspirin with hydroxyurea/aspirin have sparked an intense discussion, given that the combination of anagrelide and aspirin causes more bleeding complications in the gastrointestinal tract."4.83Anagrelide: what was new in 2004 and 2005? ( Petrides, PE, 2006)
" Randomized studies have shown that the risk of thrombosis was significantly reduced in ET with the use of hydroxyurea (HU) and in PV with the use of chlorambucil or 32P."4.80Treatment of polycythaemia vera and essential thrombocythaemia. ( Silverstein, MN; Tefferi, A, 1998)
"Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease-progression is unknown."4.12Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. ( Alvarez-Larrán, A; Angona, A; Arellano-Rodrigo, E; Ayala, R; Bellosillo, B; Caballero, G; Carreño-Tarragona, G; Cuevas, B; Del Orbe-Barreto, R; Ferrer-Marín, F; Fox, ML; García, R; García-Gutiérrez, V; García-Hernández, C; Garrote, M; Gasior, M; Gómez, M; Gómez-Casares, MT; Guerrero, L; Hernández-Boluda, JC; Magro, E; Martínez, CM; Mata-Vazquez, MI; Murillo, I; Pereira, A; Pérez-Encinas, M; Pérez-López, R; Ramírez, MJ; Raya, JM; Xicoy, B, 2022)
"Maximal fetal hemoglobin (Hb F) elevations in the baboon subsequent to phenyl hydrazine-induced hemolytic anemia, bleeding, bleeding plus hydroxyurea (HU), or cytosine arabinoside were two to three times lower than those achieved with bleeding plus 5-azacytidine (azaC)."3.67On the mechanism of Hb F elevations in the baboon by erythropoietic stress and pharmacologic manipulation. ( DeSimone, J; Hall, L; Heller, P; Lavelle, D; Zwiers, D, 1986)
"A 34% response was obtained in 202 evaluable patients in the terminal phase of chronic granulocytic leukemia using combinations of hydroxyurea, 6-mercaptopurine, and corticosteroids."3.66Combination chemotherapy for terminal-phase chronic granulocytic leukemia: cancer and leukemia group B studies. ( Cavalli, F; Coleman, M; Glidewell, O; Holland, JF; Kostinas, JE; Pajak, TF; Rai, KR; Silver, RT, 1980)
"Essential thrombocythemia is a chronic myeloproliferative neoplasm characterized by sustained thrombocytosis, bone marrow megakaryocytic hyperplasia and an increased risk of thrombosis and hemorrhage."2.49[Treatment of essential thrombocythemia]. ( Alvarez-Larrán, A; Besses, C; Cervantes, F, 2013)
"Major bleeding is rare and seems to be related to higher platelet counts."2.42Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia. ( Barbui, T; Finazzi, G, 2003)
"Venous thrombosis is more frequent in PV than in ET; superficial or deep venous thromboses are seen."2.41[What vascular events suggest a myeloproliferative disorder?]. ( Caulier-Leleu, MT; Hachulla, E; Pasturel-Michon, U; Rose, C; Trillot, N, 2000)
"Aspirin (ASS) was the most frequently used drug in 47 of 93 recorded cases (51%)."2.39Essential thrombocythemia and pregnancy. ( Griesshammer, M; Heimpel, H; Pearson, TC, 1996)
"Major bleeding is rare and seem to be related to higher platelet counts: therefore, a platelet count over 1500 x 10(9)/L is generally regarded as an indication for cytoreduction."2.39Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. ( Barbui, T; Brière, J; Dupuy, E; Finazzi, G; Kiladjian, JJ, 1996)
"Hydroxyurea treatment was initiated, leading to a gradual decrease in platelet count."1.62Differential diagnostic and treatment difficulties in a patient with acquired von Willebrand syndrome. ( Bedekovics, J; Bereczky, Z; Illés, Á; Kracskó, B; Magyari, F; Schlammadinger, Á, 2021)
"Risk of thrombosis is higher in JAK2-mutated ET."1.51Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2019)
"Hydroxyurea was the most commonly used cytoreductive therapy."1.46Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. ( Bilgir, O; Çağlıyan, G; Çekdemir, D; Cömert, M; Haznedaroğlu, İC; İlhan, O; Kaya, E; Özdemirkıran, F; Şahin, F; Saydam, G; Soyer, N; Ünal, A; Vural, F; Yılmaz, M, 2017)
"Hydroxyurea treatment was not related to leukemic transformation."1.43Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms. ( Akay, OM; Andıç, N; Bolaman, AZ; Kadıköylü, VG; Ünübol, M; Yağcı, E; Yavaşoğlu, İ, 2016)

Research

Studies (53)

TimeframeStudies, this research(%)All Research%
pre-19905 (9.43)18.7374
1990's10 (18.87)18.2507
2000's17 (32.08)29.6817
2010's17 (32.08)24.3611
2020's4 (7.55)2.80

Authors

AuthorsStudies
Alvarez-Larrán, A3
Garrote, M1
Ferrer-Marín, F2
Pérez-Encinas, M1
Mata-Vazquez, MI1
Bellosillo, B2
Arellano-Rodrigo, E1
Gómez, M2
García, R1
García-Gutiérrez, V1
Gasior, M1
Cuevas, B1
Angona, A2
Gómez-Casares, MT2
Martínez, CM1
Magro, E1
Ayala, R1
Del Orbe-Barreto, R1
Pérez-López, R1
Fox, ML1
Raya, JM1
Guerrero, L1
García-Hernández, C1
Caballero, G1
Murillo, I1
Xicoy, B2
Ramírez, MJ1
Carreño-Tarragona, G1
Hernández-Boluda, JC2
Pereira, A1
Nicol, C1
Ajzenberg, N1
Lacut, K1
Couturaud, F1
Lippert, E1
Pan-Petesch, B1
Ianotto, JC1
Cilia, K1
Borg, J1
Bugeja, M1
Farrugia, E1
Magyari, F1
Kracskó, B1
Bedekovics, J1
Bereczky, Z1
Illés, Á1
Schlammadinger, Á1
Harrison, CN3
Mead, AJ1
Panchal, A1
Fox, S1
Yap, C1
Gbandi, E1
Houlton, A1
Alimam, S1
Ewing, J1
Wood, M1
Chen, F1
Coppell, J1
Panoskaltsis, N1
Knapper, S1
Ali, S1
Hamblin, A1
Scherber, R1
Dueck, AC1
Cross, NCP1
Mesa, R1
McMullin, MF1
Tefferi, A5
Barbui, T10
Al-Sawaf, O1
Köhler, P1
Eichenauer, DA1
Böll, B1
Kochanek, M1
Shimabukuro-Vornhagen, A1
Ferrari, A1
Carobbio, A1
Masciulli, A1
Ghirardi, A1
Finazzi, G8
De Stefano, V1
Vannucchi, AM2
Cervantes, F2
Besses, C2
Fu, R1
Zhang, L1
Yang, R1
Singh, A1
Chaudhary, R1
Nityanand, S1
Martínez-Avilés, L1
Antelo, ML1
Burgaleta, C1
Mata, MI1
Martínez-Trillos, A1
Durán, MA1
Marcote, B1
Ancochea, A1
Senín, A1
Vicente, V1
Kreher, S1
Ochsenreither, S1
Trappe, RU1
Pabinger, I1
Bergmann, F1
Petrides, PE2
Koschmieder, S1
Matzdorff, A1
Tiede, A1
Griesshammer, M2
Riess, H1
Lim, Y1
Lee, JO1
Kim, SH1
Kim, JW1
Kim, YJ1
Lee, KW1
Lee, JS1
Bang, SM1
Samuelson, B1
Chai-Adisaksopha, C1
Garcia, D1
Soyer, N1
Haznedaroğlu, İC1
Cömert, M1
Çekdemir, D1
Yılmaz, M1
Ünal, A1
Çağlıyan, G1
Bilgir, O1
İlhan, O1
Özdemirkıran, F1
Kaya, E1
Şahin, F1
Vural, F1
Saydam, G1
Andıç, N1
Ünübol, M1
Yağcı, E1
Akay, OM1
Yavaşoğlu, İ1
Kadıköylü, VG1
Bolaman, AZ1
Campbell, PJ2
Bareford, D2
Erber, WN1
Wilkins, BS2
Wright, P1
Buck, G2
Wheatley, K2
Green, AR3
Rolf, N1
Suttorp, M1
Budde, U1
Siegert, G1
Knoefler, R1
Dingli, D1
Chernoff, N1
Rogers, JM1
Sonmez, M1
Saglam, F1
Karahan, SC1
Erkut, N1
Mentese, A1
Sonmez, B1
Ucar, F1
Topbas, M1
Ovali, E1
Ruggeri, M2
Rodeghiero, F3
Cazzola, M1
Barosi, G1
Grossi, A2
Gugliotta, L1
Liberato, LN1
Marchetti, M1
Mazzucconi, MG1
Tura, S1
Elliott, MA1
East, CL1
van der Walt, JD1
Reilly, JT1
Grigg, AP1
Revell, P1
Woodcock, BE1
Costello, R1
O'Callaghan, T1
Sébahoun, G1
Gisslinger, H1
Cacciola, RR1
Di Francesco, E1
Pezzella, F1
Tibullo, D1
Giustolisi, R1
Cacciola, E1
Coleman, M1
Silver, RT1
Pajak, TF1
Cavalli, F1
Rai, KR1
Kostinas, JE1
Glidewell, O1
Holland, JF1
Millicovsky, G1
DeSesso, JM1
Cortelazzo, S1
Vestri, O1
Galli, M1
van Genderen, PJ3
Michiels, JJ3
van der Poel-van de Luytgaarde, SC1
van Vliet, HH1
Heimpel, H1
Pearson, TC1
Dupuy, E1
Kiladjian, JJ1
Brière, J1
Leenknegt, H1
Silverstein, MN2
Randi, ML2
Rossi, C2
Fabris, F2
Menapace, L1
Girolami, A2
Solberg, LA1
Hachulla, E1
Rose, C1
Trillot, N1
Caulier-Leleu, MT1
Pasturel-Michon, U1
Steinheider, G1
Seidel, HJ1
Kreja, L1
Longo, G1
Rafanelli, D1
Rossi Ferrini, P1
Lavelle, D1
DeSimone, J1
Heller, P1
Zwiers, D1
Hall, L1
Gunz, FW1
Levi, JA1
Vincent, PC1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Nilotinib Combined by Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Bcr-abl Positive Acute Myeloid Leukemia[NCT01690065]Phase 246 participants (Anticipated)Interventional2012-09-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

22 reviews available for hydroxyurea and Bleeding

ArticleYear
Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis.
    Haematologica, 2019, Volume: 104, Issue:12

    Topics: Hemorrhage; Humans; Hydroxyurea; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Risk Factors;

2019
[Treatment of essential thrombocythemia].
    Medicina clinica, 2013, Sep-21, Volume: 141, Issue:6

    Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cell Transformation, Neoplastic; Disease Progress

2013
Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment.
    British journal of haematology, 2013, Volume: 163, Issue:3

    Topics: Adolescent; Age of Onset; Anticoagulants; Child; Child, Preschool; Clone Cells; Disease Progression;

2013
Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.
    Journal of thrombosis and thrombolysis, 2015, Volume: 40, Issue:4

    Topics: Hemorrhage; Humans; Hydroxyurea; Quinazolines; Thrombocythemia, Essential; Thrombosis

2015
Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.
    Current hematologic malignancy reports, 2006, Volume: 1, Issue:2

    Topics: Aged; Agranulocytosis; Alkylating Agents; Clinical Trials as Topic; Combined Modality Therapy; Disea

2006
Hypoxia and the Edema Syndrome: elucidation of a mechanism of teratogenesis.
    Birth defects research. Part B, Developmental and reproductive toxicology, 2010, Volume: 89, Issue:4

    Topics: Abnormalities, Drug-Induced; Animals; Blister; Chick Embryo; Cocaine; Edema; Epinephrine; Hematoma;

2010
Special issues in myeloproliferative neoplasms.
    Current hematologic malignancy reports, 2011, Volume: 6, Issue:1

    Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Child; Female; Hemorrhage; Humans; Hydroxyur

2011
Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia.
    Current hematology reports, 2003, Volume: 2, Issue:3

    Topics: Alkylating Agents; Hemorrhage; Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Platelet Count;

2003
Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
    Haematologica, 2004, Volume: 89, Issue:2

    Topics: Acute Disease; Adult; Aged; Alkylating Agents; Cell Transformation, Neoplastic; Child; Clinical Tria

2004
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.
    British journal of haematology, 2005, Volume: 128, Issue:3

    Topics: Aged; Aspirin; Hemorrhage; Humans; Hydroxyurea; Middle Aged; Polycythemia Vera; Risk Factors; Thromb

2005
[Treatment of essential thrombocythemia].
    La Revue de medecine interne, 2005, Volume: 26, Issue:12

    Topics: Aspirin; Enzyme Inhibitors; Hemorrhage; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha;

2005
Anagrelide: what was new in 2004 and 2005?
    Seminars in thrombosis and hemostasis, 2006, Volume: 32, Issue:4 Pt 2

    Topics: Antineoplastic Agents; Aspirin; Blood Platelets; Clinical Trials, Phase III as Topic; Drug Therapy,

2006
Update on diagnosis and management of essential thrombocythemia.
    Seminars in thrombosis and hemostasis, 2006, Volume: 32, Issue:4 Pt 2

    Topics: Age Factors; Antineoplastic Agents; Aspirin; Drug Antagonism; Female; Fibrinolytic Agents; Hemorrhag

2006
Primary thrombocythemia: diagnosis, clinical manifestations and management.
    Annals of hematology, 1993, Volume: 67, Issue:2

    Topics: Adolescent; Adult; Aged; Busulfan; Child; Diagnosis, Differential; Female; Hemorrhage; Humans; Hydro

1993
Essential thrombocythemia and pregnancy.
    Leukemia & lymphoma, 1996, Volume: 22 Suppl 1

    Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Aspirin; Busulfan; Combined Modality Therapy; Di

1996
Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
    Leukemia & lymphoma, 1996, Volume: 22 Suppl 1

    Topics: Adult; Aged; Alkylating Agents; Anemia, Megaloblastic; Arrhythmias, Cardiac; Bone Marrow Diseases; B

1996
Treatment of polycythaemia vera and essential thrombocythaemia.
    Bailliere's clinical haematology, 1998, Volume: 11, Issue:4

    Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; In

1998
The pathogenesis and management of essential thrombocythaemia.
    Haematologica, 1999, Volume: 84 Suppl EHA-4

    Topics: Acute Disease; Alkylating Agents; Aspirin; Cardiovascular Diseases; Clone Cells; Gene Expression; He

1999
A clinical update in polycythemia vera and essential thrombocythemia.
    The American journal of medicine, 2000, Aug-01, Volume: 109, Issue:2

    Topics: Age Factors; Carcinogens; Cell Transformation, Neoplastic; Chronic Disease; Enzyme Inhibitors; Femal

2000
[What vascular events suggest a myeloproliferative disorder?].
    Journal des maladies vasculaires, 2000, Volume: 25, Issue:5

    Topics: Adult; Aged; Alkylating Agents; Arterial Occlusive Diseases; Cross-Sectional Studies; Erythromelalgi

2000
Efficacy and safety of hydroxyurea in patients with essential thrombocythemia.
    Pathologie-biologie, 2001, Volume: 49, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Cell Transformation, Neoplastic; Cohort Studies; Female; Fol

2001
[Essential thrombocythemia: conventional therapy].
    Haematologica, 1991, Volume: 76 Suppl 3

    Topics: Adult; Antineoplastic Agents; Busulfan; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; Immunolo

1991

Trials

7 trials available for hydroxyurea and Bleeding

ArticleYear
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
    Blood, 2017, 10-26, Volume: 130, Issue:17

    Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Drug Resistance; Female; Hemorrhage; Humans; Hy

2017
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
    Annals of hematology, 2014, Volume: 93, Issue:12

    Topics: Aged; Aged, 80 and over; Alkylating Agents; Blood Cell Count; Busulfan; Comorbidity; Disease Progres

2014
Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jun-20, Volume: 27, Issue:18

    Topics: Biomarkers; Bone Marrow; Hemoglobins; Hemorrhage; Humans; Hydroxyurea; Leukocyte Count; Platelet Agg

2009
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Female; F

2005
Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
    Acta haematologica, 2007, Volume: 118, Issue:4

    Topics: Adult; Aged; Antithrombin III; Aspirin; Drug Therapy, Combination; Female; Fibrin Fibrinogen Degrada

2007
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.
    The New England journal of medicine, 1995, Apr-27, Volume: 332, Issue:17

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Female; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea;

1995
Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 1999, Volume: 5, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Busulfan; Disease-Free Survival; Female; Hemorr

1999

Other Studies

24 other studies available for hydroxyurea and Bleeding

ArticleYear
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
    Cancer, 2022, 07-01, Volume: 128, Issue:13

    Topics: Hemorrhage; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Neoplasms, Second Primary; Nitriles; Poly

2022
Hemorrhages in Polycythemia Vera and Essential Thrombocythemia: Epidemiology, Description, and Risk Factors-Learnings from a Large Cohort.
    Thrombosis and haemostasis, 2022, Volume: 122, Issue:10

    Topics: Aspirin; Hemorrhage; Humans; Hydroxyurea; Male; Polycythemia Vera; Risk Factors; Thrombocythemia, Es

2022
Bilateral adrenal and pulmonary haemorrhages as an initial presentation of polycythaemia vera.
    BMJ case reports, 2022, Dec-08, Volume: 15, Issue:12

    Topics: Bone Marrow; Hemorrhage; Humans; Hydrocortisone; Hydroxyurea; Hyperplasia; Male; Polycythemia Vera

2022
Differential diagnostic and treatment difficulties in a patient with acquired von Willebrand syndrome.
    Hematology (Amsterdam, Netherlands), 2021, Volume: 26, Issue:1

    Topics: Aged, 80 and over; Blood Transfusion; Enzyme Inhibitors; Hemorrhage; Humans; Hydroxyurea; Male; Thro

2021
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
    American journal of hematology, 2019, Volume: 94, Issue:1

    Topics: Adult; Aspirin; Bone Marrow; Busulfan; Disease Management; Disease Progression; Hemorrhage; Humans;

2019
Management of an adult patient with sickle cell disease and acute chest syndrome by veno-venous extracorporeal membrane oxygenation.
    Annals of hematology, 2019, Volume: 98, Issue:3

    Topics: Acute Chest Syndrome; Anemia, Sickle Cell; Anticoagulants; Combined Modality Therapy; Dobutamine; Ex

2019
Successful management of acute bleeding in essential thrombocythemia using automated cell separator.
    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2014, Volume: 50, Issue:1

    Topics: Administration, Oral; Adolescent; Automation; Blood Platelets; Body Weight; Cell Separation; Female;

2014
Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncolo
    Annals of hematology, 2014, Volume: 93, Issue:12

    Topics: Anticoagulants; Disease Susceptibility; Drug Interactions; Female; Hemorrhage; Heparin, Low-Molecula

2014
Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
    Thrombosis research, 2015, Volume: 135, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Blood Cell Count; Comorbidity; Databases, Factual;

2015
Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms.
    Turkish journal of haematology : official journal of Turkish Society of Haematology, 2017, Mar-01, Volume: 34, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Chronic Disease; Fe

2017
Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms.
    Turkish journal of haematology : official journal of Turkish Society of Haematology, 2016, Sep-05, Volume: 33, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chronic Disease; Female; Hemorrhage; Humans; Hydroxyurea

2016
Essential thrombocythaemia in a teenage girl resulting in acquired von Willebrand syndrome with joint haemorrhage and menorrhagia.
    Thrombosis and haemostasis, 2010, Volume: 103, Issue:6

    Topics: Adolescent; Antigens, CD34; Blood Cell Count; Blood Platelets; Female; Hemorrhage; Humans; Hydroxyur

2010
Treatment related changes in antifibrinolytic activity in patients with polycythemia vera.
    Hematology (Amsterdam, Netherlands), 2010, Volume: 15, Issue:6

    Topics: Adult; Aged; alpha-2-Antiplasmin; Biomarkers; Carboxypeptidase B2; Case-Control Studies; Female; Fib

2010
Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis.
    Blood, 2003, May-01, Volume: 101, Issue:9

    Topics: Adolescent; Adult; Anemia; Cohort Studies; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; Incid

2003
Towards a rational treatment of essential thrombocythemia, despite limited evidence and old prejudices.
    Haematologica, 2004, Volume: 89, Issue:2

    Topics: Adult; Cohort Studies; Disease Progression; Evidence-Based Medicine; Expert Testimony; Female; Hemor

2004
When and how to treat essential thrombocythemia.
    The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1

    Topics: Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Hydroxyurea; Leukemia

2005
Combination chemotherapy for terminal-phase chronic granulocytic leukemia: cancer and leukemia group B studies.
    Blood, 1980, Volume: 55, Issue:1

    Topics: Daunorubicin; Dexamethasone; Drug Therapy, Combination; Gastrointestinal Diseases; Hemorrhage; Human

1980
Cardiovascular alterations in rabbit embryos in situ after a teratogenic dose of hydroxyurea: an in vivo microscopic study.
    Teratology, 1980, Volume: 22, Issue:1

    Topics: Animals; Cardiac Tamponade; Cardiovascular System; Cerebral Hemorrhage; Embryo, Mammalian; Female; H

1980
Acquired von Willebrand disease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count.
    Annals of hematology, 1994, Volume: 69, Issue:2

    Topics: Adult; Bleeding Time; Female; Hemorrhage; Humans; Hydroxyurea; Mucous Membrane; Platelet Count; Skin

1994
The paradox of bleeding and thrombosis in thrombocythemia: is von Willebrand factor the link?
    Seminars in thrombosis and hemostasis, 1997, Volume: 23, Issue:4

    Topics: Aged; Alkylating Agents; Aspirin; Erythromelalgia; Female; Fibrinolytic Agents; Hemorrhage; Hemorrha

1997
Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2000, Volume: 6, Issue:1

    Topics: Acute Disease; Adult; Age Factors; Arteriosclerosis; Aspirin; Busulfan; Cohort Studies; Disease-Free

2000
Characterization of a Friend virus-replicating target cell.
    Experimental hematology, 1979, Volume: 7, Issue:9

    Topics: Animals; Blood Transfusion; Bone Marrow Cells; Cell Transformation, Viral; Colony-Forming Units Assa

1979
On the mechanism of Hb F elevations in the baboon by erythropoietic stress and pharmacologic manipulation.
    Blood, 1986, Volume: 67, Issue:4

    Topics: Anemia, Hemolytic; Animals; Azacitidine; Cytarabine; DNA; Erythropoiesis; Fetal Hemoglobin; Hemorrha

1986
The outlook for the adult with acute leukaemia, 1972.
    The Medical journal of Australia, 1972, Aug-19, Volume: 2, Issue:8

    Topics: Acute Disease; Adolescent; Adult; Aged; Bacterial Infections; Cytarabine; Drug Combinations; Female;

1972